Is AI the key to unlocking the mysteries of Alzheimer’s?

Is AI the key to unlocking the mysteries of Alzheimer’s?

An interesting article here on Fierce Biotech about a neuroimaging start-up that is aiming to take on Alzheimer’s.

They aim to do this by building maps of the brain and utilising AI to hone in on neurological inflammation, demyelination and axonal loss, which are key signs of neurodegenerative diseases.

They are then working on identifying biomarkers associated with the above and create a guide on to early indicators and diagnosis.

The CEO of the start-up, Jean-René Bélanger goes on to add “What we have is a platform that develops biomarkers based on imaging for drug development. We’re working with CROs and with pharma companies to help them extract information from the white matter that they would not see otherwise.”

You can read the full article here;


Big Pharma and Quantum Computing Team Up

Big Pharma and Quantum Computing Team Up

An interesting article on IEEE Spectrum this morning that covers the new trend of big pharma teaming up with quantum computing companies to speed up drug discovery.

This follows the recent news I have seen on my timeline that Roche has partnered with Cambridge Quantum Computing and Boehringer Ingelheim is now collaborating with Google on such projects.

Excited to see how this develops and how it will ultimately benefit the patient.

What are your thoughts on using artificial intelligence on drug discovery projects? Feel free to share your story with us. We are always open to guest blog writers who have an interesting science or engineering story to tell.

You can read more here;

#medicaldevices #biotechnology #drugdiscovery #newtoncolmore



By continuing to use the site, you agree to the use of cookies. more information

The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.